Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

the Company's 2008 restructuring plans.

Other expense net, decreased by $58,162 from $83,859 in other expense in 2008 to $25,697 in other expense in 2009. The reduction is related to the decreased interest income of $42,285 from a decline in cash and cash equivalents offset by a $92,973 reduction in interest expense attributable to reduced debenture interest and a $7,474 decrease in translation gains and losses that were recorded at our Rehovot location. In the third quarter of 2009 the Company recorded $29,606 in interest expense related to the remaining of $1,000,000 in convertible debentures issued on January 3, 2008.

Nine-months Ended September 30, 2009

For the nine months ended September 30, 2009, Pharmos recorded a net loss of $7.3 million, or $0.16 per share compared to a net loss of $9.1 million, or $0.35 per share for the nine months ended September 30, 2008. Total operating expenses decreased 27% to $6.6 million from $9.0 million.

Research & development expenses decreased by $2,940,572 or 41% from $7,206,909 in 2008 to $4,266,337 in 2009, related to the Company's primary focus of cash resources on the Dextofisopam Phase 2b trial and the downsizing and curtailment of general research and development programs. The decline reflects decreases in virtually every research and development expense category. The primary reductions include a $724,000 reduction in payroll, a $327,000 reduction in consultant and professional fees, a $1,547,000 reduction in clinical studies and $342,000 reduction in various other areas. The decrease in these costs reflect the closing of the Rehovot facility effective October 31, 2008 and the fact that the Dextofisopam trial is complete.

In the first nine months of 2009, the Company completed a Phase 2b trial of its lead compound, Dextofisopam, in female IBS patients. The Phase 2b trial was fully enrolled on April 9, 2009 at 324 patients. Costs of $3,946,000 were inc
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... N.C., Oct. 26 WomanCare Global is pleased ... portfolio to include Roselle®, a combined oral contraceptive ... and 30 micrograms of ethinylestradiol and Optinor®, a ... micrograms of levonorgestrel. (Logo: ...
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... presenting at the Oppenheimer 21st Annual Healthcare Conference in New ... on Tuesday, November 2, 2010 at 11:25 a.m. Eastern Time ... and may be accessed on the Company,s website at ...
Cached Medicine Technology:WomanCare Global Acquires 2 Global Brands From ICON -- Combined Oral Contraceptive Roselle® and Emergency Contraceptive Optinor® 2
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in ... the holiday season, AlignLife looks forward to their annual toy ... Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as ... are able to give kids toys for Christmas who would ... generosity of our patients." , The 70 toys were donated ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... . All these items are brand new; they are made ... updated with the new range of high quality prom gowns. ... iFitDress.com’s designs are made according to the latest trends. For ... outfit from the company is handpicked by skilled tailors. , ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... the University of Aberdeen in the UK say in a ... linked to increased risk of asthma in kids//. The study ... team showed that low vitamin E in mothers was linked ... ,In this study researchers followed 1,000 children at five years. ...
... village died after eating wild poisonous mushrooms while their mother ... Begma, 8, Neelma, 5, and Jaywanti, 2, died Friday in ... here. ,All the children fell unconscious and died ... 30, managed to survive but is still recovering from food ...
... improve donor lung quality as part of the San ... number of available donor lungs and transplant procedures without ... survival. ,The study appears in the second ... Respiratory and Critical Care Medicine, published by the American ...
... Carolina Wilmington announce the continuation of funding to study ... ultimately// yield treatments. The National Institute of Environmental Health ... to further delve into the acute and chronic effects ... Florida's west coast. ,"Preliminary studies with red ...
... in the Sun's brightness over the past millennium have ... to a review of existing results and new calculations// ... Germany. ,The review, led by Peter Foukal (Heliophysics, ... Among the coauthors is Tom Wigley of the National ...
... the inner lining of the nose are linked to ... current treatments according// to researchers at John Hopkins University. ... the misery of persistent inflammation of the moist tissue ... is clogged passages and recurring infections, according to the ...
Cached Medicine News:Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:"Beach to Bedside" Study Focuses on Effects of Inhaled Toxins 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
...
...
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Medicine Products: